Patent US4617306A successfully refreshed from Google Patents.
US4617306A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist
Assignee: FIRST NATIONAL STATE BANK NEWARK NEW JERSEY
•
Filing: 1985-09-13
•
Granted: 1986-10-14
•
Expires: 2005-09-13
Abstract
Abstract Pharmaceutical preparations comprising (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof and (b) a calcium antagonist or a pharmaceutically acceptable salt thereof, as well as the treatment of hypertension/migraine by co-administration of components (a) and (b), e.g. in the form of a composition as defined.
Inventors
- 👤 Dieter Welzel
- 👤 Hans Buhlmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/48; A61P; A61P25/00; A61P25/04; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
50 words
A method of treating hypertension comprising co-administering to a subject in need of such treatment: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being co-administered in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 2
Independent Claim
50 words
A method of treating hypertension comprising co-administering to a subject in need of such treatment: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being co-administered in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 3
Dependent Claim
16 words
A method according to claim 1 wherein co-administration of (a) and (b) is effected substantially concomitantly.
Claim 4
Independent Claim
51 words
A method of treating migraine headaches comprising co-administering to a subject in need of such treatment: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being co-administered in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 5
Independent Claim
51 words
A method of treating migraine headaches comprising co-administering to a subject in need of such treatment: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being co-administered in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 6
Dependent Claim
16 words
A method according to claim 3 wherein co-administration of (a) and (b) is effected substantially concomitantly.
Claim 7
Dependent Claim
50 words
A pharmaceutical preparation useful in treating hypertension and migraine headaches comprising: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being present in the pharmaceutical preparation in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 8
Dependent Claim
50 words
A pharmaceutical preparation useful in treating hypertension and migraine headaches comprising: (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof; and (b) as a calcium antagonist, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester; said components (a) and (b) being present in the pharmaceutical preparation in a ratio of 1:2.5 to 1:25 p.p.w.
Claim 9
Dependent Claim
24 words
A preparation according to claim 5 wherein (a) and (b) are present in a ratio of 1.0 to 7.5 mg: 5.0 to 75 mg.
Claim 10
Dependent Claim
17 words
A preparation according to claim 6 wherein the ratio is 2.0 to 5.0 mg:10 to 60 mg.
Claim 11
Dependent Claim
17 words
A preparation according to claim 7 wherein the ratio is 2.0 to 4.0 mg:10 to 30 mg.
Claim 12
Dependent Claim
15 words
A preparation according to claim 8 wherein the ratio is 2.0 to 4.0 mg:20 mg.
Claim 13
Dependent Claim
10 words
A preparation according to claim 5 in unit dosage form.
Claim 14
Dependent Claim
44 words
A preparation according to claim 5 in solid, enteric-coated form wherein component (a) is in the form of a solid solution of a pharmaceutically acceptable non-cross-linked poly-N-vinylpyrrolidone-2-polymer having an average molecular weight of from 10,000 to 100,000 and a pharmaceutically acceptable polyoxyalkylene cholesteryl ether.
Claim 15
Dependent Claim
11 words
A preparation according to claim 5, wherein (a) is co-dergocrine mesylate.
Claim 16
Dependent Claim
14 words
A preparation according to claim 5 wherein the ratio is 1:5 to 1:10 p.p.w.
Claim 17
Dependent Claim
12 words
A preparation according to claim 13 wherein the ratio is 1:10 p.p.w.
Claim 18
Dependent Claim
12 words
A preparation according to claim 9 wherein the ratio is 2.0:20 mg.
Claim 19
Dependent Claim
28 words
A preparation according to claim 10 comprising (a) and (b) in an amount of from 1.0 to 7.5 mg of (a) and 5.0 to 75 mg of (b).
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-13 | 1990-04-14 | 1990-10-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-13 | 1994-04-14 | 1994-10-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-13 | 1998-04-14 | 1998-10-14 | $7700.00 | Window Closed / Lapsed |